Michigan Biosciences Industry Association Logo

Federal Advocacy

Stay updated on federal initiatives and policies influencing the bio-industry across the country. This category highlights national-level advocacy efforts, initiatives, and developments driving innovation and growth across the industry.

Advocacy Advocacy : Federal Advocacy Advocacy : State Advocacy Association Updates Event Event : Industry Event Event : MichBio Advocacy Events Event : MichBio Networking Event Event : MichBio Signature Event Event : MichBio Webinar Event : Partner Event Member Feature News News : Industry News News : Member News News : MichBio News/Statement News : Michigan News
NIH Licensing Guidelines Put Life Sciences Innovation at Risk 
Posted In: Federal Advocacy,
Date posted Oct 2

The Trump Administration has chosen to uphold NIH’s new “access planning” licensing guidelines, a regulatory shift...

Read Post
Parsing A New Drug Pricing Deal and What It Means for Innovation 
Posted In: Federal Advocacy,
Date posted Oct 2

The September 30, 2025, announcement that Pfizer will cut prices on selected drugs (particularly for Medicaid and uninsured populations), tied...

Read Post
SBIR/STTR Programs at Risk: Coalition Calls on Congress for Swift Reauthorization
Posted In: Federal Advocacy,
Date posted Sep 4

The future of two cornerstone federal programs—the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR)...

Read Post
Approach to Federal Grantmaking Takes Worrisome Turn
Posted In: Federal Advocacy,
Date posted Sep 4

On August 7, 2025, the Administration issued Executive Order 14332 – Improving Oversight of Federal Grantmaking - marking a fundamental...

Read Post
Congressional Advocates Seek Expedited Disbursement of Critical NIH Funding
Posted In: Federal Advocacy,
Date posted Jul 29

U.S. Senator Katie Britt (R-AL), a member of the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related...

Read Post
SBIR/STTR Reauthorization Update: Legislative Efforts Intensify as Program Deadline Approaches
Posted In: Federal Advocacy,
Date posted Jul 29

As the September 30, 2025 sunset date looms for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR)...

Read Post
Controversial New Patent Fee Model Emerges
Posted In: Federal Advocacy,
Date posted Jul 29

The Trump administration, according to a July 28, 2025 Wall Street Journal article (subscription-based), is reportedly exploring a major overhaul...

Read Post
Key Measures for Biosciences Industry Still Being Debated as OBBBA Inches Forward
Posted In: Federal Advocacy,
Date posted Jul 1

The "One Big Beautiful Bill" is a piece of legislation currently being debated in Congress that among many other items, includes provisions...

Read Post
Trump Administration Issues EO Invoking a Most Favored Nation (MFN) Drug Pricing Policy
Posted In: Federal Advocacy,
Date posted May 21

In the ongoing debate over soaring prescription drug costs in the United States, one policy proposal has gained significant attention: the...

Read Post
Patent Eligibility Restoration Act (PERA) Reintroduced
Posted In: Federal Advocacy,
Date posted May 21

U.S. Senators Thom Tillis (R-NC), Chairman of the Senate Judiciary Subcommittee on Intellectual Property, and Chris Coons (D-DE), and...

Read Post
Citizen Petition Filed Against FDA's Call for Animal Testing Alternatives
Posted In: Federal Advocacy,
Date posted May 9

A citizen petition has been filed objecting to the FDA's recent call for alternatives to animal testing, arguing that it could lead to reliance on...

Read Post
Reports Document FDA Review Delays: What It Means for Drug Manufacturers
Posted In: Federal Advocacy,
Date posted Apr 24

Recent reports have highlighted growing concerns over delays in the U.S. Food and Drug Administration's (FDA) drug review processes, particularly...

Read Post